title: How Melanoma Resists PD-1 Blockade.
abstract: Researchers at the University of California, Los Angeles, have shed light on mechanisms by which melanoma cells become resistant to PD-1 blockade with pembrolizumab. One mechanism involves loss-of-function mutations in JAK1 or JAK2 that abolish interferon-γ signaling; the other involves a truncating mutation in B2M that results in defective antigen presentation.
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007371:Interferon-gamma; D008545:Melanoma; D061026:Programmed Cell Death 1 Receptor
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D061026:Programmed Cell Death 1 Receptor; D007371:Interferon-gamma; C582435:pembrolizumab